Samrat Pharmachem Ltd
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
- Market Cap ₹ 129 Cr.
- Current Price ₹ 416
- High / Low ₹ 572 / 320
- Stock P/E 6,433
- Book Value ₹ 205
- Dividend Yield 0.26 %
- ROCE 34.9 %
- ROE 30.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.6%
Cons
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.1.11 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
70 | 72 | 65 | 47 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 268 | |
63 | 71 | 64 | 46 | 62 | 69 | 87 | 108 | 131 | 170 | 197 | 287 | 267 | |
Operating Profit | 6 | 1 | 1 | 1 | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 1 |
OPM % | 9% | 2% | 1% | 2% | 2% | 5% | 6% | 3% | 5% | 5% | 11% | 8% | 0% |
0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Profit before tax | 6 | 1 | 0 | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 0 |
Tax % | 35% | 31% | 41% | 35% | 33% | 37% | 35% | 29% | 27% | 27% | 27% | 26% | |
4 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 0 | |
EPS in Rs | 12.23 | 1.29 | 0.78 | 1.04 | 0.97 | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 | 0.06 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 27% |
3 Years: | 31% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | 45% |
5 Years: | 39% |
3 Years: | 58% |
TTM: | -100% |
Stock Price CAGR | |
---|---|
10 Years: | 34% |
5 Years: | 37% |
3 Years: | 28% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 28% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 9 | 10 | 10 | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 60 |
3 | 4 | 3 | 3 | 6 | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 20 | |
16 | 17 | 15 | 10 | 17 | 14 | 13 | 14 | 25 | 19 | 30 | 34 | 27 | |
Total Liabilities | 32 | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 110 |
4 | 4 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | |
CWIP | 3 | 4 | -0 | -0 | -0 | 0 | -0 | -0 | 1 | -0 | -0 | -0 | -0 |
Investments | -0 | -0 | -0 | -0 | 2 | -0 | -0 | -0 | -0 | -0 | 0 | 2 | 2 |
25 | 27 | 24 | 19 | 27 | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 97 | |
Total Assets | 32 | 34 | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 116 | 110 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | -2 | 4 | -1 | -0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | |
-4 | -1 | -0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | |
2 | 1 | -1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | |
Net Cash Flow | 2 | -2 | 2 | -0 | -0 | -1 | -1 | 1 | -1 | -0 | 14 | -3 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 55 | 60 | 63 | 74 | 93 | 59 | 86 | 69 | 74 | 67 | 72 | 60 |
Inventory Days | 46 | 54 | 45 | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 |
Days Payable | 86 | 89 | 87 | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 |
Cash Conversion Cycle | 15 | 25 | 21 | 36 | 26 | 58 | 70 | 52 | 61 | 53 | 51 | 61 |
Working Capital Days | 27 | 37 | 25 | 39 | 35 | 61 | 65 | 56 | 63 | 54 | 44 | 62 |
ROCE % | 49% | 9% | 7% | 7% | 5% | 16% | 23% | 12% | 22% | 24% | 52% | 35% |
Documents
Announcements
- Compliance Certificate Under Regulation 40(9), (10) Of SEBI (LODR) Regulations, 2015, For The Year Ended March 31, 2024 18 Apr
- Compliance Certificate Under Regulation 7(3) For The Period: 01St April 2023 To 31St March, 2024 10 Apr
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 10 Apr
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 10 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Reg. 74(5) for the quarter ended March 31, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
SPL manufactures pharmaceutical ingredient products. It is a major supplier of Iodine Derivatives to the Indian and Foreign Market
and is also present in Salt, Animal Feed, Textile & Tyre Cord manufacturing segment. Company's facilities approved by leading regulatory agencies such as USFDA, GMP, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA